Shares of Apollo Hospitals jumped over 6 per cent in early trade on Thursday, hitting Rs 7,393.75 on the Bombay Stock Exchange (BSE) after the company reported impressive results for the second quarter of the financial year .

In Q2FY25, Apollo Hospitals reported a 63% year-on-year increase in net profit to Rs 379 crore, mainly driven by growth in its hospital business. This is an increase from Rs 233 crore in the same quarter last year.

EBITDA also saw a strong performance, growing 30% year-on-year to Rs 816 crore. The healthcare services division, which encompasses the hospital business, reported revenue growth of 14 per cent year-on-year, reaching Rs 2,903 crore. EBITDA margins in this segment amount to 24.9%.

The overall hospital occupancy rate improved to 73%, compared to 68% during the same period last year, supported by a notable increase in patient numbers. Inpatient (IP) volumes increased 8.3%, while new outpatient (OP) registrations increased 10%. Apollo Hospitals currently operates 9,423 beds across its network.

Revenue from its diagnostics and retail healthcare business grew 14% year-on-year to Rs 404 crore, while Apollo HealthCo, the digital healthcare and omnichannel pharmacy platform, saw an increase by 17% YoY, reaching Rs 2,282 crore in Q2FY25.

Following the results, JP Morgan maintained an overweight on the stock, with a price target of Rs 7,200. The brokerage noted that the results were in line with expectations, citing healthy revenue growth across all segments, from high occupancy rates, improved hospital EBITDA margins and positive margin growth at Apollo Health & Lifestyle (AHLL).

Over the past year, Apollo Hospitals shares have gained nearly 35%, including a 21.3% rise in 2024 alone. The stock has appreciated 15% over the past six months .